Literature DB >> 518142

Maintenance dose of penicillamine in rheumatoid arthritis: a comparison between a standard and a response-related flexible regimen.

H F Hill, A G Hill, A T Day, R M Brown, J R Golding, W H Lyle.   

Abstract

There is much individual variation in the response of rheumatoid arthritis (RA) to penicillamine, some patients deriving benefit from very small doses. A dose of 750 mg daily is widely regarded as standard, and, while their RA commonly responds, many patients discontinue treatment because of adverse reactions to penicillamine. A more flexible prescribing policy might be more successful in the long term and was tested in 1 group of 20 patients, another receiving a 'standard' regimen, each beginning treatment at a low dose level. Of those who were given increases of dose only if response was poor 17 completed 1 year of treatment on an average maintenance dose of 308 mg daily, but only 11 of the other group on an average dose 613 mg daily. Proteinuria, which was found only in the latter group accounted for 6 withdrawals, all at doses of 625 mg daily or above. The reduction in rheumatoid activity appeared to be of about the same degree among the members of both groups who completed 12 months of treatment. Penicillamine should be given initially in a low dose and this should be raised only if there is lack of response after at least 4 weeks.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 518142      PMCID: PMC1000387          DOI: 10.1136/ard.38.5.429

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  4 in total

1.  Penicillamine treatment of rheumatoid arthritis with a single daily dose of 250 mg.

Authors:  I A Jaffe
Journal:  Proc R Soc Med       Date:  1977

2.  Treatment of rheumatoid arthritis with penicillamine.

Authors:  H F Hill
Journal:  Semin Arthritis Rheum       Date:  1977-05       Impact factor: 5.532

3.  Penicillamine in rheumatoid disease with particular reference to rheumatoid factor.

Authors:  I A Jaffe
Journal:  Postgrad Med J       Date:  1968-10       Impact factor: 2.401

4.  Penicillamine in rheumatoid disease: a long-term study.

Authors:  A T Day; J R Golding; P N Lee; A D Butterworth
Journal:  Br Med J       Date:  1974-02-02
  4 in total
  7 in total

1.  Penicillamine nephropathy.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-07

2.  Myopathy due to mercaptopropionyl glycine.

Authors:  M A Mansell
Journal:  Br Med J (Clin Res Ed)       Date:  1982-11-06

Review 3.  Antirheumatic drugs: clinical pharmacology and therapeutic use.

Authors:  G L Craig; W W Buchanan
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

4.  D-penicillamine withdrawal in rheumatoid arthritis.

Authors:  M J Ahern; N D Hall; K Case; P J Maddison
Journal:  Ann Rheum Dis       Date:  1984-04       Impact factor: 19.103

5.  Natural course of penicillamine nephropathy: a long term study of 33 patients.

Authors:  C L Hall; S Jawad; P R Harrison; J C MacKenzie; P A Bacon; P T Klouda; A G MacIver
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-16

6.  Eosinophilia in D-penicillamine therapy.

Authors:  D H Smith; D L Scott; G C Zaphiropoulos
Journal:  Ann Rheum Dis       Date:  1983-08       Impact factor: 19.103

7.  Age and arthritis.

Authors:  G Holden
Journal:  J R Soc Med       Date:  1982-06       Impact factor: 18.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.